SRR5088923
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- ALLOGRAFT_REJECTION+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- MYC_TARGETS_V2+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- IL6_JAK_STAT3_SIGNALING+0.200
- INFLAMMATORY_RESPONSE+0.200
- MITOTIC_SPINDLE+0.200
Top 10 suppressed
- BILE_ACID_METABOLISM-0.300
- COAGULATION-0.200
- P53_PATHWAY-0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.200
- XENOBIOTIC_METABOLISM-0.200
- ANGIOGENESIS-0.100
- APICAL_SURFACE-0.100
- CHOLESTEROL_HOMEOSTASIS-0.100
- DNA_REPAIR-0.100
- FATTY_ACID_METABOLISM-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7c4477a6-c744-412a-8571-bfb62f0dc714 | — | — | 0.765 |
| 2 | TCGA-91-6848-01A-11R-1949-07 | — | cohortA1 | 0.763 |
| 3 | TCGA-A2-A0YM-01A-11R-A109-07 | — | E | 0.760 |
| 4 | TCGA-56-6546-01A-11R-1820-07 | — | cohortMD1 | 0.754 |
| 5 | TCGA-85-7699-01A-11R-2125-07 | — | cohortSQ1 | 0.747 |
| 6 | SRR5088924 | — | — | 0.742 |
| 7 | TCGA-BA-6873-01A-11R-1873-07 | — | — | 0.742 |
| 8 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.737 |
| 9 | TCGA-CF-A1HS-01A-11R-A13Y-07 | — | — | 0.735 |
| 10 | TCGA-50-6590-01A-12R-1858-07 | — | cohortA1 | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |